No Prescription |
 |
 | ||
|
Glez Glucotrol |
|
| ||
No Prescription » Prescription Drugs 8 » Glez Glucotrol Glipizide is an anti-diabetic drug (sulfonylurea-type) used along with a proper diet and exercise program to control high blood sugar. It is used in patients with type 2 diabetes (non-insulin-dependent diabetes). It works by stimulating the release of your body's natural insulin. Controlling high blood sugar helps prevent kidney damage blindness nerve problems loss of limbs and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Buy Glez Glucotrol and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About Glez Glucotrol: Product Type: Prescription Drugs 8 Glez ( Glucotrol Generic Glipizide ) Glez (Glucotrol Generic Glipizide) Glucotrol Generic Glipizide 2.5mg 2.5mg Tabs 5mg Tabs 100 Tablets 200 Tablets 400 Tablets 30 (3 x 10) Glucotrol Generic Glipizide Glez
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
